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ABSTRACT
We review the present knowledge of  telomeres and telomerase with special attention to their role in 
hematological disorders especially bone marrow failure syndromes including acquired aplastic anemia and 
myelodysplastic syndromes, as well as acute and chronic myeloid leukemia. The current understanding on the 
role of  telomere and telomeres dysfunctions in hematological disorders leads us to a better understanding 
on the pathology of  the diseases as well as considering some possibilities to employ the measurement of  
telomere length and telomere activity in disease prognostication. Several treatment options targeting telomere 
and telomerase being developed are also reviewed.
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Telomeres
Telomeres are the non-encoding regions 
of  DNA cappingthe ends of  chromosomes, 
in association with various proteins, known as 
shelterin. The DNA that forms the telomere 
consists of  thesequence (5′-TTAGGG-3′) n, 
which is referred to as a “telomeric repeat” 
due to its tandem repeat over 5 to15 kilobases 
(kb). A single-stranded 3’-hydroxyl overhang is 
generated by the catalytic addition of  telomeric 
repeats to the 3’ end and by post replicative 
processing of  the lagging strand.1 This single 
stranded overhang folds back and invades the 
double-stranded telomeric helix, forming the 
T loop in order to avoid being recognized as 
a double-strand break and corrected by DNA 
repair machineries.2 Thus, telomeres function 
to guard chromosomes against degradation, 
fusion, and rearrangements during DNA 
replication.3 When telomeres become very 
short, they signal the arrest of  cell proliferation, 
senescence, and apoptosis. The cells whose 
telomeres shorten to a “critical length” enter 
a stage termed replicative senescence whereby 
cell division is prevented.1
The shelterin complex is formed by 
the double-stranded DNA binding proteins. 
These proteins include TRF1, TRF2, TIN2, 
POT1, TPP1, and RAP1. TRF1 is thought 
to regulate telomere length by preventing the 
elongation of  telomeres once they reach a 
critical size. TRF2 appears to be important for 
stabilizing the chromosome ends by associating 
with the 3′ overhang and suppressing end-to-
end fusions between chromosomes. Other 
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additional proteins can bind indirectly to 
telomeres, often via TRF1 and TRF2, and 
together these proteins function to regulate 
telomere homeostasis. They consist of  RAP1-a 
binding partner of  TRF2,POT1- a single-
stranded DNA binding protein; and the two 
bridging proteins, TIN2 and TPP1.4 Not 
only do these proteins function in protecting 
the chromosome end, they also function in 
telomere length regulation. Any mutations 
reducing their expression or impairing their 
binding to DNA result in telomere erosion. 
Telomere length is maintained within a strict 
range throughout cell division, suggesting a 
negative feedback loop involving the shelterin 
complex. Due to the exquisite specifi city of  
these DNA binding proteins, the amount of  
shelterin protein bound to telomeres is roughly 
proportional to their length.2
Telomerase
Telomerase is a DNA polymerase required 
to catalyze DNA synthesis to maintain telomere 
length. It is composed of  two essential subunits, 
human telomerase RNA component (hTERC) 
and human telomerase catalytic component 
(hTERT). hTERT uses the telomerase RNA 
component (TERC) as a template to synthesize 
telomereDNA.1 The assembly of  a functional 
telomerase holoenzyme complex also requires 
other telomere- and/or telomerase-associated 
proteins (e.g., dyskerin, NOP10, GAR1, 
NHP2)to stabilize the complex.5 The structural 
organization of  hTERT can be divided 
into three functional domains which at 
the N terminus are the telomerase-specifi c 
domains required for functional assembly 
of  the enzyme complex by mediating TERT 
interaction with its TER RNA partner and the 
Figure 1. Telomeres are located at the ends of  linear chromosomes; they are composed 
of  hundreds to thousands of  tandem DNA repeat sequences: hexameric TTAGGG in the 
leading strand and CCCTAA in the lagging strand in humans. Protective proteins associated 
with telomere DNA are collectively termed shelterin (TRF1, TRF2, TIN2, POT1, TPP1, and 
RAP1). The 3’end of  the telomeric leading strand terminates as a single-stranded overhang, 
which folds back and invades the double-stranded telomeric helix, forming the T loop.1 
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homodimerization of  the protein (i.e., TERT 
protein-protein interaction). The functional 
reverse transcriptase (RT) domain is almost 
centrally located. The C-terminal domains 
of  TERTs are also required for telomerase-
specific enzymatic activity and/or in the 
telomeric nucleotide addition processivity 
process.5 
Telomerase is regulated by a wide variety 
of  genes or multifactorial. Removal or reduced 
regulation of  the hTERC subunit leads to a loss 
of  telomerase activity, erosion of  telomeres 
and inhibition of  cellular growth. Mutation 
of  the hTERC gene has been described 
in distinct autosomal dominant disorder 
dyskeratosis congenita.6 Besides its function 
as a binding site for the SP1 transcription 
factor, the hTERT promoter also provides 
other binding sites for various transcription 
factors and hormone responsible elements. 
hTERT is repressed by retinoblastoma protein 
(Rb) and cyclin-dependent kinase inhibitor 
p21WAF1. Conversely, c-Myc activates TERT 
gene expression. hTERT phosphorylation 
is another mechanism of  telomerase activity 
regulation. It is expressed mainly in embryonic 
and adult stem cells, highly proliferative cells 
such as mature lymphocytes, and in cancer 
cells, but not in most mature cells.5 While 
hTERC is expressed in relatively identical 
amount in embryonic and somatic tissues, the 
expression of  hTERT is precisely regulated 
and undetectable in many somatic cells. This 
means that the expression of  hTERT is the 
limiting step in telomerase activation.6 
Quantitative assays are available for 
telomere length and telomerase enzymatic 
activity. Telomeres can be visualized by 
fluorescent in situ hybridization (FISH) 
of  individual cells and in-flow cytometry 
of  specific cell populations (Young ASH).
The length of  telomere can be determined 
by a modification of  Southern blotting in 
which the analysis of  chromosome terminal 
restriction fragments (TRFs), as visualized 
with a radiolabeled telomeric repeat probe, 
provides the average lengths of  all telomeres 
in a cell population. It also can be measured 
by quantitative polymerase chain reaction 
amplifi cation assays. Telomerase activity can be 
measured in vitro by a sensitive and effi cient 
polymerase chain reaction (PCR)-based 
detection method, also known as telomeric 
repeat amplifi cation protocol (TRAP).7
Telomere and on cogenesis
Most cancers show gross derangement 
in chromosome numbers. Telomere attrition 
has also been proposed as a mechanism for the 
Figure 2. The Telomerase Complex and 
Its Components. The enzyme telomerase 
reverse transcriptase (TERT), its RNA 
component (TERC), the protein dyskerin, 
and other associated proteins (NHP2, 
NOP10, and GAR1) are shown.1
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loss or gain of  chromosomes. When telomere 
maintenance is disrupted in yeast, the few cells 
that escape senescence show chromosome 
abnormalities, end-to-end fusions, and 
consequent formation of  dysenteric and 
circularized chromosomes. In the absence 
of  telomerase, genetic lesions increase due 
to terminal chromosome deletions and 
repeated cycles of  break–fusion– bridge 
rearrangements. In “knock-out” mice that lack 
the RNA template component of  telomerase, 
telomeres shorten progressively with each 
generation, producing chromosomal instability 
by end-to-end fusions.9,10 Most unstable cells 
are removed by apoptosis, but they can be 
rescued if  DNA damage is not inadequately 
monitored: in mTERC–/– mice that also are 
defi cient in the tumor suppressor gene p53, a 
variety of  carcinomas appear associated with 
nonreciprocal translocations, as seen in human 
cancers.11
Figure 3. Telomere shortening activates p53 
and drives formation of  epithelial cancers 
through gene amplifi cation and deletion. 
Telomeres shorten progressively with cell 
division due to the end-replication problem 
in settings of  insufficient telomerase, 
including in human fibroblasts, aging 
tissues, early cancers and diseases of  
high cellular turnover. Critical telomere 
shortening compromises the telomere cap 
and results in a DNA damage response 
that activates the p53 tumor suppressor 
protein. This activation of  p53 induces 
replicative senescence in cultured human 
fi broblasts, impairs stem cell self-renewal, 
induces apoptosis in tissue progenitor 
cells, causes premature aging and strongly 
suppresses tumor formation. If  p53 is 
mutated or deleted, these responses to 
telomere dysfunction are mitigated and 
chromosomal fusions are tolerated. The 
generation of  fused chromosomes results 
in dysenteric chromosomes (chromosomes 
with two centromeres) and when these attach 
to opposite spindle poles, chromosome 
breakage occurs. These broken ends serve 
as potent catalysts for translocations, focal 
amplifi cations and focal deletions. Such 
CNAs drive development of  carcinomas 
and explain the widespread gene copy 
number changes seen in human cancers.15
In humans, telomere length has been 
linked to malignant transformation— to the 
onset of  cancer—in several diseases. When 
telomeres were first noted to be short in 
colorectal cancer, telomere loss was speculated 
to contribute to tumor genesis and genetic 
instability.12 Telomerase defi ciency has been 
reported in the histologically normal mucosa 
of  inflammatory bowel disease. Losses of  
chromosomes in no dysplastic tissue of  
ulcerative colitis patients was correlated with 
telomere shortening and associated with the 
appearance of  anaphase bridges, especially in 
patients who progressed to cancer.13 The major 
risk factor for esophageal cancer is the chronic 
infl ammation of  Barrett’s esophagus, the result 
of  years of  exposure to gastroesophageal 
reflux. Leukocyte telomere length at first 
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presentation is inversely proportional to the 
risk of  later esophageal cancer, hypothesized 
to refl ect a genetic predisposition to repair 
with persistent oxidative stress.14 Telomerase 
has also been reported to be up regulated in 
more than 90% of  invasive breast cancers.15 An 
epidemiology study namely the Long Island 
Breast Cancer Study Project conducted among 
1,067 cases and 1,110 controls, provided the 
strongest evidence to date that breast cancer 
risk may be affected by telomere length among 
premenopausal women or women with low 
dietary intake of  antioxidants or antioxidant 
supplements.16 An analysis of  the relative 
telomere length (RTL) of  peripheral blood 
cells in relation to breast cancer incidence 
and prognosis including 265 newly diagnosed 
breast cancer patients and 446 female controls 
resulted that long RTL was a significant 
independent negative prognostic factor 
(hazards ratio, 2.92; 95% CI, 1.33–6.39; P = 
0.007) in breast cancer patients with advanced 
disease.16
Telomere and telomerase in 
hematological disorders
Telomere and telomerase in bone 
marrow failure syndromes
Dyskeratosis congenita is  a rare 
cons t i tu t iona l  bone  mar row fa i lu re 
syndrome stereotypically characterized by 
mucocutaneous abnormalities (nail dystrophy, 
hyperpigmentation, and leukoplakia) and 
aplastic anemia in childhood. Patients with 
dyskeratosis are at increased risk for malignancies, 
pulmonary fi brosis, and liver cirrhosis.17 The 
genetic basis study of  dyskeratosis congenita 
found X-linked dyskeratosis congenita to 
associate with mutations in the DKC1 gene 
which produces dyskerin associated with 
TERC. Patients’ leukocytes showed reduced 
telomerase activity which explains the erosion 
of  their chromosomes. The discovery that 
autosomal dominant dyskeratosis is caused 
by heterozygous mutations or large deletions 
in TERC established dyskeratosis congenita 
as a disease of  telomerase insufficiency.18 
Homozygous mutations in TERT43 and in 
NOP10, a telomerase-associated protein, were 
described in some families with autosomal 
recessive dyskeratosis congenita.19 More 
recently, mutations in TINF2, which encodes 
TIN2, a shelterin protein that caps and protects 
the telomeres, have been identifi ed in a third 
of  patients with dyskeratosis congenita, further 
implicating abnormal telomere maintenance in 
the pathophysiology of  the disease.20
In acquired aplastic anemia, an immune 
pathophysiology that targets hematopoietic 
stem cells has been inferred in most cases of  
acquired aplastic anemia from the hematologic 
response to immunosuppressive therapies; 
failure to respond to such treatments might 
be due to a non-immune etiology or to 
properties of  the hematopoietic compartment, 
a quantitatively severe loss of  stem cell number 
or a qualitative abnormality of  stem and 
progenitor cells.21 When some patients with 
acquired aplastic anemia were found to have 
accelerated leukocyte telomere attrition, the 
cause was initially presumed to be secondary, 
a physiologic response to stem cell “stress.”22-24 
The discovery of  the genetic basis of  telomere 
erosion in dyskeratosis congenita made it 
plausible that some patients with acquired 
marrow failure also might have abnormal 
telomerase function as a basis for telomere 
shortening. The functional consequences of  
the genetic changes in TERC were reduced 
telomerase activity of  patient primary cells, 
very short telomeres of  leukocytes, and 
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low telomerase activity in vitro.23 TERC 
mutations in either dyskeratosis congenita 
or acquired aplastic anemia are similar at the 
molecular level and produce the same effects 
on telomerase function, despite the diversity 
of  clinical phenotypes (Table 1); an exception 
is large TERC gene deletions observed in 
dyskeratosis congenita families only.18 In cohort 
studies, the frequency of  TERC mutations was 
low (approximately 4% of  all patients with 
acquired aplastic anemia).26,27 Careful study 
of  some families showed that healthy relatives 
of  patients carrying TERC mutations also 
had short telomeres, some mild hematologic 
abnormalities (macrocytosis, mild anemia, 
thrombocytopenia, or granulocytopenia), 
reduced progenitor cells in peripheral blood, 
increased serum hematopoietic growth factors, 
and hypoplastic bone marrows.26 One report 
that possibly explained potential clinical 
relevance of  sometimes modest hematologic 
fi ndings in healthy relatives of  patients carrying 
TERC mutations was dramatically reported 
in hematopoietic stem cell graft failure in one 
proband, whose unknowingly affected sibling 
donor provided only very low numbers of  
CD34 cells from both marrow and mobilized 
blood collected in multiple leukaphereses.28 
A study on mutations in TERT, the gene 
encoding the telomerase reverse transcriptase 
itself, found that approximately 4% of  patients 
with apparently acquired aplastic anemia had 
TERT mutations that disrupted telomerase 
activity, causing short telomeres  of  leukocytes 
and a hematopoietic stem cell compartment 
of  limited proliferative capacity.29 Several 
patients with TERT mutations also have a 
family history of  blood dyscrasias, especially 
myelodysplastic syndrome evolving to acute 
myeloid leukemia, further suggesting a common 
genetic background for these disorders. As 
with TERC, apparently healthy relatives 
with TERT mutations had short telomeres 
and reduced hematopoietic function.29 The 
association between TERT mutations and 
aplastic anemia has been confirmed.29,30 A 
few patients with marrow failure have genetic 
variants and specific haplotypes for genes 
coding for shelterin components (TERF1 and 
TERF2) that might contribute to disease by 
disrupting the telomere homeostasis.31
Despite the various mutations reported 
in the telomerase complex, the question 
whether mutations suffi cient to cause disease 
remains due to great variability is in the 
phenotype. Various clinical outcomes related 
with mutations in telomerase complex genes 
including isolated aplastic anemia, isolated 
pulmonary fibrosis or hepatic cirrhosis or 
multiorgan dyskeratosis congenita. The same 
mutation either in TERC or TERT in a single 
pedigree can associate with aplastic anemia 
in one patient, and pulmonary fibrosis or 
hepaticcirrhosis in another, suggesting that 
other factors contribute to organ damage. As 
an example, telomerase-mutant patients with 
pulmonary fibrosis often have a smoking 
history, suggesting this environmental insult as 
a trigger. Conversely, many relatives of  patients 
with aplastic anemia with the same telomerase 
mutation have low telomerase activity, short 
telomeres, a hypoplastic bone marrow, and 
reduced hematopoietic function, but they 
are clinically healthy and asymptomatic.28,29 
Although disease anticipation may play 
a role in determining manifestation, the 
hypoplasticbone marrow of  the TERC- or 
TERT-mutant individuals appears capable 
of  maintaining hematopoiesis under normal 
conditions, but may be hypothesized to be 
more susceptible to environmental injury, such 
as viral infections, drug exposure, or immune 
attack. Low telomerase function may result 
in a quantitative defi ciency by reducing the 
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number of  hematopoietic stem cells able to 
maintain hematopoiesis, as well as a qualitative 
defect by impairing hematopoietic stem cell 
regeneration. Higher serum interferon γ and 
a limited T-cell receptor (TCR) Vβ usage in 
telomerase mutant patients—similar to the 
skewed T-cell population typically observed 
in patients with immune acquired aplastic 
anemia32—consistent with oligoclonal T-cell 
expansion and immune destruction of  marrow 
as pathophysiologic had also been reported in 
these patients also.31 A telomerase mutation 
does not appear to be suffi cient to determine 
aplastic anemia, but healthy relatives in which 
telomeres are short and/or a mutation need to 
be further observed in long-term prospective 
studies.20  Since the number of  acquired aplastic 
anemia patients with identified mutation 
of  either TERC or TERT genes or related 
genes are much fewer than those with short 
telomeres, it is suggested that other genetic 
lesions or environmental factors also may 
contribute to accelerated telomere erosion. 
In addition to aging, some environmental 
factors are known to cause telomere attrition. 
Smoking34 and even psychological stress35 have 
correlated with leukocyte telomere shortening. 
Over demanded or “stressed” hematopoiesis 
also can result in telomere erosion. Excessive 
Figure 4. Proposed model for the role of  dysfunctional and short telomeres in the pathogenesis 
of  human disease. Aging, bone marrow stress, and genetic factors, such as mutations in 
telomerase complex genes (TERT, TERC, DKC1, and NOP10), shelterin components (TINF2, 
TERF1, and TERF2), or in other genes (SBDS and DDX11) produce progressive telomere 
erosion. Excessive telomere shortening results in defective cell proliferation, senescence, 
apoptosis, and genomic instability. Environmental factors, such as viruses, drugs, smoking, 
or asbestos exposure, may contribute to telomere shortening as well as injury to an organ 
with limited regeneration capacity, thus triggering disease development (aplastic anemia, 
pulmonary fi brosis, and hepatic cirrhosis). Short telomeres also promote genomic instability, 
breakagefusion- bridge cycles, and aneuploidy, which can lead to myelodysplasia (MDS) or 
leukemia (AML).1
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telomere shortening has been observed in 
the fi rst years after allogeneic bone marrow 
transplantation in comparison with donor 
leukocytes, consistent with increased stem 
and progenitor turnover to replenish the 
bonemarrow.36 Chemotherapy for solid tumors 
also causes myelotoxicity, requiring increased 
hematopoietic regeneration to recover blood 
cell counts, and premature telomere shortening 
has been observed following multiple cycles of  
cytotoxic drug therapy.37 These observations 
are consistent with a contribution of  “stress” 
hematopoiesis secondary to environmental 
factors to telomere shortening in aplastic anemia. 
However, the degree of  telomere shortening 
produced in these clinical circumstances 
has been mild, less than 1 kb erosion in 
telomere lengths, as compared with theextreme 
attrition observed in individual mutations in 
telomerasedeficiency (usually more than 3 
kb). Other bone marrow failure syndromes 
involving teomeres shortening including 
Fanconi anemia, werner syndrome,  Bloom 
syndrome, Nijmegen breakage syndrome, and 
Shwachman-Diamond syndrome.20
Telomere and telomerase in 
hematologic neoplasia 
Normal hematopoietic cells express 
telomerase activity,however the presence 
of  telomerase does not necessarily imply 
stable and thus unchanging telomere length. 
Therefore, before considering the telomere and 
telomerase status of  leukemias and lymphomas 
we need to understand telomerase activity in 
normal hematopoietic cells as seen in Figure 5. 
The level of  telomerase activity was different 
inhuman HSCs and their differentiate progeny. 
In contrast to somatic cells that lacktelomerase 
activity, it is clear that many hematopoieticcells 
are telomerase-competent. Primitive HSCs 
arelikely to be quiescent most of  the time 
and thus thepopulation of  cells exhibits a low 
level of  telomerase activity. However, upon 
stimulation to proliferate,telomerase activity 
Figure 5.  Telomerase activity in normal hematopoietic cell populations38
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appears to be upregulated in theirimmediate 
progeny and may help to slow down therate of  
telomere erosion. The more mature cells then 
become quiescent again and down-regulate 
telomeraseactivity. The telomeres of  HSCs 
shorten, probably dueto inadequate levels 
of  telomerase activity that slow but do not 
prevent telomere erosion. Both T cells and 
monocyte/B cells in peripheral blood also had 
low telomerase activity which was elevated when 
either cell types was cultured with mitogen. 
The highest in vivo telomerase expression in 
normal T cells is present in thymus, followed by 
T cells in the tonsil. The germinal center B-cells 
also show high telomerase activity. Thus, 
telomerase may play a permissive role inT cell 
and B cell development and in determining 
thecapacity of  lymphoid cells for cell division 
and clonalexpansion. In summary, HSCs and 
lymphocytes are telomerase competent and 
mortal. The gradual telomere loss with aging 
and rapid cycling of  HSCs or lymphocytes 
might contribute to immunosenescence, 
exhausted hematopoiesis, and increased 
likelihood of  malignant transformation. 
Another interesting clinical aspect of  these 
fi ndings is the future possibility of  selectively 
upregulated telomerase and controlling 
telomere length in certain cell types in order 
to achieve a delayed induction of  replicative 
senescence. (reviewed in ref  38).
Acute Myeloid Leukemia and 
Myelodysplasia Syndrome 
The overall importance of  telomerase in 
the pathogenesis of  AML has recently been 
confi rmed by the demonstration that hTERT 
is necessary for growth of  primary AML cells 
in a mouse model.37 A number of  studies have 
investigated telomerase activity and telomere 
length in mononuclear cells (MNC) from 
patients with MDS and AML (reviewed in 
ref.39). Calado et al examined three cohorts 
of  AML patients who show no physical signs 
of  DC for sequence variation in the hTERT 
and hTERC genes. They identifi ed three novel 
missense mutations in hTERT, and, while 
the V299M sequence change did not seem 
to affect telomerase enzymatic activity when 
tested by the TRAP assay, both the P65A and 
R522K mutations conferred dramatic defects. 
Surprisingly, they also identifi ed three AML 
patients who are homozygous for sequence 
changes previously identifi ed in a heterozygous 
state in AA patients and controls (A1062T and 
del441E). Thus, it appears that hTERT gene 
variants have low penetrance and are carried 
in patients with a wide variety of  disorders. 
This phenomenon can be explained if  short 
telomeres, as opposed to mutation status of  
telomerase, mediate disease pathogenesis, a 
hypothesis consistent with the fact that the 
median age at presentation for AML is 70.40 
Telomere shortening was signifi cantly 
more pronounced in patients with cytogenetic 
alterations as compared with patients with 
normal karyotypes. In this study, the shortest 
median telomere length wasfound in the 
group with complex cytogenetic abnormalities.
hTERT was overexpressed in patients with 
complex karyotypes, followed by patients with 
noncomplex karyotypes and patients without 
karyotypic changes.41 This might suggest 
that with increasing telomere attrition, by 
either replication-dependent or replication-
independent  mechanisms,kar yotyp ic 
abnormalities becomes more pronounced 
and, as a consequence, telomerase upregulation 
becomes essential to prevent replicative 
senescence of  the malignant clone. However,it 
has recently been suggested that telomerase 
expression in the context of  short telomeres 
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does not necessarily prevent cells from reaching 
replicative exhaustion.42
Because of  the uneven distribution of  
telomere length on individual chromosome 
arms, critical shortening of  telomeres on 
particular chromosomes could promote 
the formationof  chromosomal aberrations 
and contribute to clonal evolution. This 
hypothesis remains relevant even if  the average 
telomerelength remains well above the critical 
level of  shortening.43 Distinct groups of  AML 
that are characterized either by aberrations that 
could result from telomere dysfunction (terminal 
deletions, gains/losses of  chromosome 
parts, or nonreciprocaltranslocations) or 
by aberrations that are unlikely to result 
fromtelomere dysfunction (e.g., reciprocal 
translocations or inversions)could serve as 
an ideal model to study the effect oftelomere 
shortening and telomerase activity during 
tumorigenesis.44
Chronic Myeloid Leukemia 
Most probably due to an increased 
tur nover  of  the  BCR-ABL-pos i t ive 
haematopoietic compartment, myeloid 
cellsfrom 123 patients with CML show 
accelerated telomereshortening. In Ph+ 
peripheralblood leukocytes, telomere length 
is approximately 1 kb shorter than in age-
matched controls. Taking into account that 
roughly 100 bp (50–200 bp) are lost per 
celldivision in somatic cells the reduced 
telomerelength in CP CML cells indicates 
that, at a given point of  time, leukaemic 
BCR-ABL-positive haematopoietic stemcells 
have undergone an excess of  approximately 
10 cell divisions as compared to their normal 
polyclonalcounterparts (HSC). Furthermore, 
telomere length measurements of  cells 
obtainedfrom CML patients suffering from 
different stages of  disease showed signifi cantly 
shorter telomeres in AP and BP than in CP sd 
revealed by telomere fl uorescence and Southern 
Blot analysis (reviewed in ref  43). Successful 
therapy with IM was found to be associated 
with an increase in mean telomere length 
(Figure 3) refl ecting a treatment-induced shift 
from virtually 100% BCR-ABL+ peripheral 
blood cells topredominantly polyclonal, BCR-
ABL haematopoiesis.46,47
Clinical implication of  telomere 
and telomerase roles in 
hematological disorders
Bone marrow failure syndrome
A telomerase mutation does not appear to 
be suffi cient to determine aplastic anemia, but 
healthy relatives in which telomeres are short 
and/or a mutation need to be further observed 
in long-term prospective studies.20 Besides 
this, protection from environmental stress 
should be minimized to prevent further hits for 
bone marrow failure development in acquired 
aplastic anemia. For most syndromes in which 
telomere shortening is known to bepathogenic, 
hematopoietic stem cell transplantation is the 
onlypotential cure. Modulation of  telomerase 
activity may have a role in thetreatment 
of  telomere deficiency syndromes such as 
dyskeratosis congenita and telomerase-mutant 
acquired aplastic anemia. Clinical observations 
suggest that androgen therapy can induce 
improvements in peripheral blood counts, 
achieving transfusion independence in as many 
as 60% of  patients.17 Androgens stimulate 
telomerase gene expression in hematopoietic 
cells, includingCD34+ cells and lymphocytes, 
and this mechanism of  action may explain their 
The Journal of  Internal Medicine, Acta Interna, Volume 4, Number 2, Desember 2014: 87-101
97 
efficacy in hematologic disease.47  Androgen 
therapy may cause severe adverse events, such 
as hepatocarcinoma andpeliosis hepatis, and liver 
function must be monitored. For patients with 
acquired aplastic anemia, hematopoietic stemcell 
transplantation and intensive immunosuppression 
with antithymocyteglobulin and cyclosporine are 
the main therapies.21 Immunosuppressive therapy 
seems to be relatively or entirely ineffective for 
dyskeratosis congenita. Patients with acquired 
aplastic anemia and short telomeres appears to 
have poorer responses to immunosuppression. 
However, this relationship was retrospectively 
observed, and prospective studies of  the 
prognostic value of  telomere length are required 
before such measurements infl uence therapeutic 
decisions. Some patients with aplastic anemia 
with telomerase complex mutations respond 
hematologically to androgen treatment,48 as do 
patients with dyskeratosis congenita.
Acute leukemia
Concepts of  telomere and telomerase in 
acute leukemia are helpful for understanding the 
pathophysiology of  the disease. Nevertheless, 
whatever the role of  hTERT in determining the 
prognosis inAML, it is unlikely to surpass that of  
cytogenetics in discriminatingrisk groups yet.20 
In primary AML samples, the transfection with 
dominant negative hTERT reduced the number 
of  colony forming units (CFU) and decreased 
engraftment of  leukaemic cells transplanted into 
a immunodefi cient mouse model.49
Chronic myeloid leukemia
In the BCR-ABL+ CML celline K562, 
50% of  the expanded clones underwent 
apoptosis afterdetectable telomere shortening 
when transduced with thedominant negative 
form of  hTERT.50 Competitive inhibition 
of  the catalytic activity of  telomerase has 
beenattained by the small molecule inhibitor 
BIBR1532 as well as by the oligonucleotid 
GRN163L both in vitro and in vivo experiments. 
However, in the BCR-ABL-positive K562 cell 
line, BIBR1532 mediated telomerase inhibition 
was insuffi cient to induce telomere mediated 
apoptosis, while the expression of  a dominant 
negative hTERTmutant in the respective cell 
line induced an increased rate of  apoptosis 
(mostly refl ecting terminal‘crisis’ cells) and 
augmented radiosensitivity.50 GRN163L 
produced a decreased concentration ofthe 
compound required for telomerase inhibition 
and a better biodistribution in normal and 
malignant tissue.51 
Transcriptional inhibition of  
essential telomerase components
Short interfering RNA (siRNA) causes the 
degradation ofthe corresponding mRNA in cells. 
In in vitro and in vivo experiments, telomerase 
activity was successfully downregulatedby 
the introduction of  siRNA against TERT. 
Antisense-oligodesoxynucleotides (ODNs),a 
short DNA fragment which is complimentary 
to therespective target RNA, after hybridization 
with hTERCRNA, caused an inhibition of  the 
RNA function andthus lead to a direct decrease 
of  telomerase activity. Highly increased rates 
of  apoptotic cells were observed in cellculture 
experiments with glioma, prostate carcinoma 
and ovarian cancer cell lines (reviewed in 
ref.44). It may be assumed that non- or slowly 
dividing somatic cells do not experience critical 
shorteningof  telomere length, while in fast 
growing malignant cells with a high telomerase 
activity, a critical telomere shortening can be 
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achieved earlier resulting in a mitoticcatastrophe 
and consequently apoptosis and necrosis. 
However, it needs to be emphasized that an 
effective treatment will require time and effects 
will appear with delay which may potentially 
lasting from months to years, as shown in 
fi gure 4.
Figure 4. Simultaneous inhibition of  
telomerase and bcr-abl tyrosine kinase 
may overcome emergence of  resistance. (A) 
Telomerase inhibitor alone: while telomeres 
shorten in response to treatment the 
malignant clone continues to proliferate. 
Depending on initial telomere length, 
telomeres become critically short after a 
distinct amount of  time leading to cell 
senescence and apoptosis. (B) CML Phþ 
cells are generally sensitive to tyrosine 
kinase inhibitors. However, secondary 
resistant subclones can emerge under 
therapy. (C) Combined treatment with 
tyrosine kinase and telomerase inhibitors 
represses the clonal expansion of  tyrosine 
kinase resistant cells.44
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